Effect of tolbutamide, glyburide and glipizide administered supraspinally on CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
Abstract
Sulfonylureas are widely used oral drugs for the treatment of type II diabetes mellitus. In the present study, the effects of sulfonylureas administered supraspinally on kainic acid (KA)-induced hippocampal neuronal cell death and hyperglycemia were studied in ICR mice. Mice were pretreated intracerebroventricularly (i.c.v.) with 30μg of tolbutamide, glyburide or glipizide for 10min and then, mice were administered i.c.v. with KA (0.1μg). The neuronal cell death in the CA3 region in the hippocampus was assessed 24h after KA administration and the blood glucose level was measured 30, 60, and 120m...
Source: Brain Research - April 5, 2014 Category: Neurology Authors: Kim CH, Park SH, Sim YB, Kim SS, Kim SJ, Lim SM, Jung JS, Suh HW Tags: Brain Res Source Type: research
Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation
Conclusions
Sitagliptin increases insulin secretion and reduces fasting and postprandial plasma glucose in renal transplant recipients with NODAT. The short-term treatment was well tolerated, and sitagliptin seems safe in this population. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - March 27, 2014 Category: Urology & Nephrology Authors: Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., Jenssen, T. Tags: Renal Transplantation Source Type: research
Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes
Conclusion and ImplicationsStandard glucose‐lowering therapeutic agents demonstrated significant acute glucose lowering in male gkwt/del mice at doses corresponding to therapeutic free drug levels in man, suggesting the potential of these mice as a translatable model of human T2D. Novel GKAs also lowered glucose in this mouse model. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - March 18, 2014 Category: Drugs & Pharmacology Authors: D J Baker, A M Atkinson, G P Wilkinson, G J Coope, A D Charles, B Leighton Tags: Research Paper Source Type: research
Investigating the role of plasma glucose concentration as a phenotypic marker for CYP2C9 genetic variants, in the diabetic population of Gujarat
D Bhatt, N Chauhan, A Sharma, D Dhawan, RV Bhatt, S Phatak, H PadhIndian Journal of Pharmaceutical Sciences 2014 76(1):72-77The present study was aimed to investigate the role of plasma glucose concentration as a phenotypic marker and to study the frequency distribution of CYP2C9 genetic variants in Gujarat state diabetic population. One hundred and nine unrelated diabetes mellitus patients treated with sulfonylureas were genotyped for CYP2C9*2 and CYP2C9*3 alleles. Their pre- and posttreatment postprandial blood glucose levels were recorded and mean glucose drop per milligram of drug values were calculated and further use...
Source: Indian Journal of Pharmaceutical Sciences - March 11, 2014 Category: Drugs & Pharmacology Authors: D BhattN ChauhanA SharmaD DhawanRV BhattS PhatakH Padh Source Type: research
Pharmacoepidemiologic and in Vitro Evaluation of Potential Drug‐Drug Interactions of Sulfonylureas with Fibrates and Statins
ConclusionsUse of fenofibrate or gemfibrozil together with glyburide was associated with elevated overall risks for serious hypoglycemia. CYP inhibition seems unlikely to explain this observation. We speculate that a pharmacodynamic effect of fibrates (e.g., activate peroxisome proliferator‐activator receptor alpha) may contribute to these apparent interactions. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - February 18, 2014 Category: Drugs & Pharmacology Authors: H Schelleman, X Han, C M Brensinger, S K Quinney, W B Bilker, D A Flockhart, L Li, S Hennessy Tags: Drug safety Source Type: research
Fewer deaths/strokes/revascularizations with metformin than glipizide.
PMID: 24444583 [PubMed - in process] (Source: American Family Physician)
Source: American Family Physician - January 15, 2014 Category: Primary Care Authors: Shaughnessy AF Tags: Am Fam Physician Source Type: research
Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules.
Abstract
Glipizide (GPZ) has been widely used in the treatment of type-2 diabetics as insulin secretogague. Multiunit chitosan based GPZ floating microspheres was prepared by ionotropic gelation method for gastroretentive delivery using sodiumtripolyphosphate as cross-linking agent. Pharmacokinetic study of microspheres was done in rabbit and plasma samples were analyzed by a newly developed and validated high-performance liquid chromatographic method. Method was developed on Hypersil ODS-18 column using a mobile phase of 10mM phosphate buffer (pH, 3.5) and methanol (25:75, v/v). Elute was monitored at 230...
Source: International Journal of Biological Macromolecules - January 10, 2014 Category: Biochemistry Authors: Pani NR, Acharya S, Patra S Tags: Int J Biol Macromol Source Type: research
Comment on Hong et Al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
PMID: 24356605 [PubMed - in process] (Source: Diabetes Care)
Source: Diabetes Care - December 23, 2013 Category: Endocrinology Authors: Lund SS, Gong Y Tags: Diabetes Care Source Type: research
Response to comment on Hong et Al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311.
PMID: 24356606 [PubMed - in process] (Source: Diabetes Care)
Source: Diabetes Care - December 23, 2013 Category: Endocrinology Authors: Hong J, Zhang Y, Lai S, Ning G Tags: Diabetes Care Source Type: research
Do geriatrics require dose titration for antidiabetic agents?
Conclusion: A substantial dose reduction of glibenclamide (25%), gliclazide (25%), glimepiride (22%), and metformin (5%) in geriatrics compared to nongeriatrics was observed. Smaller dosage formulations like 0.75 mg glibenclamide, 0.5 mg glimepiride, 20 mg gliclazide, and 250 mg metformin may be of value in geriatric diabetic practice. (Source: Journal of Postgraduate Medicine)
Source: Journal of Postgraduate Medicine - December 17, 2013 Category: Internal Medicine Authors: R ShastryP AdhikariA KamathM ChowtaS UllalMRSM Pai Source Type: research
The beneficial effect of metformin on β‐cell function in non‐obese Chinese subjects with newly diagnosed type 2 diabetes
ConclusionsMetformin improved β‐cell function in non‐obese subjects with newly diagnosed T2DM, which was partly independent of the change in insulin sensitivity in these subjects. This study provides evidence‐based data to support metformin use in non‐obese patients with T2DM as the first‐line agent, which can improve both insulin sensitivity and β‐cell function. Copyright © 2013 John Wiley & Sons, Ltd. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - November 14, 2013 Category: Endocrinology Authors: Y. Bi, G. Y. Tong, H. J. Yang, M. Y. Cai, J. H. Ma, J. Liang, B. Xin, H. Miao, Z. H. Peng, D. L. Zhu Tags: Research Article Source Type: research
Characterisation of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes
Conclusions and implicationsStandard glucose lowering therapeutic agents demonstrated significant acute glucose lowering in male gkwt/del mice at exposures corresponding to therapeutic free drug levels in man, suggesting the potential of these mice as a translatable model of human T2D. Novel GKAs also show glucose lowering efficacy in this mouse model. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - November 6, 2013 Category: Drugs & Pharmacology Authors: D J Baker, A M Atkinson, G P Wilkinson, G J Coope, A D Charles, B Leighton Tags: Research Paper Source Type: research
The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
Abstract
Bile acid sequestrants can potentially bind to concomitant drugs. Single-dose studies evaluated the effects of colesevelam on the pharmacokinetics of glimepiride, glipizide extended-release (ER), and olmesartan medoxomil. Each study enrolled healthy subjects aged 18-45 years. The olmesartan medoxomil study used a randomized adaptive crossover design that initially compared olmesartan medoxomil alone versus simultaneously with colesevelam, then olmesartan medoxomil alone versus 4 hours before colesevelam. The other studies used a three-period crossover design (test drug alone, test drug simultaneou...
Source: The Journal of Clinical Pharmacology - September 10, 2013 Category: Drugs & Pharmacology Authors: He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, Wight D Tags: J Clin Pharmacol Source Type: research
In Reply to ‘Primary Objective of Study of Sitagliptin in Patients With ESRD on Dialysis’
In our recent editorial regarding the study “Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial,” we said, “Thus, the study was underpowered to compare sitagliptin and glipizide on glucose lowering, which was its original intent.” (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - September 1, 2013 Category: Urology & Nephrology Authors: Wendy L. St. Peter, Eric D. Weinhandl, Michael F. Flessner Tags: Letters to the Editor Source Type: research
Primary Objective of Study of Sitagliptin in Patients With ESRD on Dialysis
We appreciate the opinion provided in the editorial by St. Peter et al on our AJKD article, and we agree that there is need for further research of the efficacy and safety of antihyperglycemic agents in patients with severely decreased kidney function and diabetes. However, we would like to clarify a point made in the editorial related to the intent of the study. St. Peter et al accurately describe the difficulty experienced in enrolling the originally planned sample size of 150 participants (75 per arm) and the discontinuation rate observed in the study, but the statement that this resulted in a study that was underpowere...
Source: American Journal of Kidney Diseases - September 1, 2013 Category: Urology & Nephrology Authors: J.C. Arjona Ferreira, G.T. Golm, B.J. Goldstein Tags: Letters to the Editor Source Type: research
